Nicoderm Cq Patent Expiration

Nicoderm Cq is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is protected by 5 US drug patents filed from 2013 to 2015 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 22, 2021. Details of Nicoderm Cq's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8075911 Transparent transdermal nicotine delivery devices
May, 2021

(3 years ago)

Expired
US8999379 Transparent transdermal nicotine delivery devices
Feb, 2020

(4 years ago)

Expired
US8663680 Transparent transdermal nicotine delivery devices
Feb, 2020

(4 years ago)

Expired
US9205059 Transparent transdermal nicotine delivery devices
Dec, 2019

(5 years ago)

Expired
US5508038 Polyisobutylene adhesives for transdermal devices
Apr, 2013

(11 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nicoderm Cq's patents.

Given below is the list of recent legal activities going on the following patents of Nicoderm Cq.

Activity Date Patent Number
Patent litigations
Expire Patent 15 Jan, 2024 US8075911
Expire Patent 15 Jan, 2024 US9205059
Maintenance Fee Reminder Mailed 31 Jul, 2023 US8075911
Maintenance Fee Reminder Mailed 31 Jul, 2023 US9205059
Expire Patent 15 May, 2023 US8999379
Maintenance Fee Reminder Mailed 28 Nov, 2022 US8999379
Expire Patent 11 Apr, 2022 US8663680
Maintenance Fee Reminder Mailed 25 Oct, 2021 US8663680
Payment of Maintenance Fee, 8th Year, Large Entity 30 May, 2019 US8075911
Payment of Maintenance Fee, 4th Year, Large Entity 23 May, 2019 US9205059


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Nicoderm Cq and ongoing litigations to help you estimate the early arrival of Nicoderm Cq generic.

Nicoderm Cq's Litigations

Nicoderm Cq been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 28, 2010, against patent number US8075911. The petitioner , challenged the validity of this patent, with Robert M. Gale as the respondent. Click below to track the latest information on how companies are challenging Nicoderm Cq's patents.

Last updated on December 10, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8075911 June, 2010 Decision
(25 May, 2011)
Robert M. Gale

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Nicoderm Cq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nicoderm Cq's family patents as well as insights into ongoing legal events on those patents.

Nicoderm Cq's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Nicoderm Cq's generic launch date based on the expiry of its last outstanding patent is estimated to be May 22, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Nicoderm Cq Generic API suppliers:

Nicotine is the generic name for the brand Nicoderm Cq. 1 company has already filed for the generic of Nicoderm Cq. Check out the entire list of companies who have already received approval for Nicoderm Cq's generic

How can I launch a generic of Nicoderm Cq before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Nicoderm Cq's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Nicoderm Cq's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Nicoderm Cq -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
7 mg/24 hrs 14 mg/24 hrs 21 mg/24 hrs 30 May, 2014 1 22 May, 2021 Extinguished

Alternative Brands for Nicoderm Cq

Nicoderm Cq which is used for reducing withdrawal symptoms and nicotine cravings during smoking cessation., has several other brand drugs using the same active ingredient (Nicotine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Haleon Us Holdings
Nicorette
Pfizer Inc
Nicotrol


Apart from brand drugs containing the same ingredient, some generics have also been filed for Nicotine, Nicoderm Cq's active ingredient. Check the complete list of approved generic manufacturers for Nicoderm Cq





About Nicoderm Cq

Nicoderm Cq is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for reducing withdrawal symptoms and nicotine cravings during smoking cessation. Nicoderm Cq uses Nicotine as an active ingredient. Nicoderm Cq was launched by Chattem Sanofi in 1996.

Approval Date:

Nicoderm Cq was approved by FDA for market use on 02 August, 1996.

Active Ingredient:

Nicoderm Cq uses Nicotine as the active ingredient. Check out other Drugs and Companies using Nicotine ingredient

Treatment:

Nicoderm Cq is used for reducing withdrawal symptoms and nicotine cravings during smoking cessation.

Dosage:

Nicoderm Cq is available in film, extended release form for transdermal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
14MG/24HR FILM, EXTENDED RELEASE Over the counter TRANSDERMAL
7MG/24HR FILM, EXTENDED RELEASE Over the counter TRANSDERMAL
21MG/24HR FILM, EXTENDED RELEASE Over the counter TRANSDERMAL